Theravance Biopharma Phase 4 PIFR-2 study of YUPELRI fails to meet primary endpoint vs Spiriva HandiHaler in severe COPD

Theravance Biopharma, Inc.

PIFR-2 study did not show statistically significant difference on primary endpoint (change in trough FEV1 at Day 85) for YUPELRI vs Spiriva HandiHaler.
Both arms demonstrated similar lung function improvement; YUPELRI safety and tolerability consistent with prior studies.
Study enrolled adults with severe to very severe COPD (FEV1 <50% predicted) and suboptimal PIFR (<55 L/min).
CEO Rick E Winningham noted growth opportunities ahead for YUPELRI, an important COPD maintenance option.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.